Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression, J&J said in a news release on Tuesday, Jan. 21. The decision came after a ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third indication for the novel antidepressant. Spravato (esketamine) has become ...

The FDA in 2019 approved Spravato, a close chemical relation to ketamine, in combination with an oral antidepressant for adults with treatment-resistant depression. Spravato generated sales of $ ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant ...

has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value threshold. The spray – which was approved by the FDA in ...

The Daily Gate mobile app brings you the latest local breaking news, updates, and more. Read the Daily Gate on your mobile device just as it appears in print.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday. MDD ...